Literature DB >> 28086085

Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities.

Liang Liu1, Xueyan Li2, Jiuyu Wang1, Min Wang1, Peng Chen2, Maolu Yin2, Jiazhi Li2, Gang Sheng1, Yanli Wang3.   

Abstract

C2c2, the effector of type VI CRISPR-Cas systems, has two RNase activities-one for cutting its RNA target and the other for processing the CRISPR RNA (crRNA). Here, we report the structures of Leptotrichia shahii C2c2 in its crRNA-free and crRNA-bound states. While C2c2 has a bilobed structure reminiscent of all other Class 2 effectors, it also exhibits different structural characteristics. It contains the REC lobe with a Helical-1 domain and the NUC lobe with two HEPN domains. The two RNase catalytic pockets responsible for cleaving pre-crRNA and target RNA are independently located on Helical-1 and HEPN domains, respectively. crRNA binding induces significant conformational changes that are likely to stabilize crRNA binding and facilitate target RNA recognition. These structures provide important insights into the molecular mechanism of dual RNase activities of C2c2 and establish a framework for its future engineering as a RNA editing tool.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C2c2; CRISPR-Cas; HEPN domain; RNA-guided RNA cleavage; endonuclease; precursor crRNA

Mesh:

Substances:

Year:  2017        PMID: 28086085     DOI: 10.1016/j.cell.2016.12.031

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  88 in total

Review 1.  Programmable RNA manipulation in living cells.

Authors:  Yu Pei; Mingxing Lu
Journal:  Cell Mol Life Sci       Date:  2019-07-31       Impact factor: 9.261

2.  A seed motif for target RNA capture enables efficient immune defence by a type III-B CRISPR-Cas system.

Authors:  Saifu Pan; Qi Li; Ling Deng; Suping Jiang; Xuexia Jin; Nan Peng; Yunxiang Liang; Qunxin She; Yingjun Li
Journal:  RNA Biol       Date:  2019-05-26       Impact factor: 4.652

3.  Structural basis for self-cleavage prevention by tag:anti-tag pairing complementarity in type VI Cas13 CRISPR systems.

Authors:  Beibei Wang; Tianlong Zhang; Jun Yin; You Yu; Wenhao Xu; Jianping Ding; Dinshaw J Patel; Hui Yang
Journal:  Mol Cell       Date:  2021-01-19       Impact factor: 17.970

Review 4.  A decade of discovery: CRISPR functions and applications.

Authors:  Rodolphe Barrangou; Philippe Horvath
Journal:  Nat Microbiol       Date:  2017-06-05       Impact factor: 17.745

5.  Grc3 programs the essential endoribonuclease Las1 for specific RNA cleavage.

Authors:  Monica C Pillon; Mack Sobhany; Mario J Borgnia; Jason G Williams; Robin E Stanley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-26       Impact factor: 11.205

6.  Structural insights into Cas13b-guided CRISPR RNA maturation and recognition.

Authors:  Bo Zhang; Weiwei Ye; Yangmiao Ye; Huan Zhou; Abdullah F U H Saeed; Jing Chen; Jinying Lin; Vanja Perčulija; Qi Chen; Chun-Jung Chen; Ming-Xian Chang; Muhammad Iqbal Choudhary; Songying Ouyang
Journal:  Cell Res       Date:  2018-11-13       Impact factor: 25.617

Review 7.  Class 2 CRISPR-Cas RNA-guided endonucleases: Swiss Army knives of genome editing.

Authors:  Stefano Stella; Pablo Alcón; Guillermo Montoya
Journal:  Nat Struct Mol Biol       Date:  2017-10-16       Impact factor: 15.369

8.  High-Resolution Cryo-EM Maps and Models: A Crystallographer's Perspective.

Authors:  Alexander Wlodawer; Mi Li; Zbigniew Dauter
Journal:  Structure       Date:  2017-08-31       Impact factor: 5.006

9.  Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors.

Authors:  Silvana Konermann; Peter Lotfy; Nicholas J Brideau; Jennifer Oki; Maxim N Shokhirev; Patrick D Hsu
Journal:  Cell       Date:  2018-03-15       Impact factor: 41.582

10.  A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity.

Authors:  Alexander J Meeske; Ning Jia; Alice K Cassel; Albina Kozlova; Jingqiu Liao; Martin Wiedmann; Dinshaw J Patel; Luciano A Marraffini
Journal:  Science       Date:  2020-05-28       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.